In neuromyelitis optica spectrum disorder (NMOSD), early initiation of effective immunosuppressive therapy to prevent further relapse is imperative because even a single relapse can have devastating consequences. Several immunosuppressive treatments have been shown to be effective in preventing relapse. However, not all patients respond favourably to each treatment, possibly owing to several factors including variability in disease activity and differences in pharmacokinetics and pharmacodynamics of drugs among patients. Thus, identification of predictors of the most suited treatment regimens for individual patients with NMOSD may help guide treatment decisions.
In their Journal of Neurology, Neurosugery & Psychiatry study, Stellmann et al1 report retrospective multicenter cohort study from Germany on the efficacy of immunotherapy and predictors for NMOSD attacks in patients undergoing immunotherapy. Azathioprine and rituximab reduced the risk of NMOSD attacks more than interferon β (IFN-β) did, while mitoxantrone and glatiramer acetate did not. Age, antibody status and previous attacks...
from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/2rSVatx
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου